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Background/aim: This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to
emphasize the points that we think will make a difference compared to randomized controlled studies.
Materials and methods: The patients who accepted to participate in the study in whom rivaroxaban (15–20 mg) and apixaban (2.5–5
mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully
accessed through the hospital automation system were included in the study.
Results: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apixaban were women. The mean age
was 73.34 ± 10.45 years, and the age range was 41–98. There was no significant difference in terms of demographic characteristics,
background information of the patients, and the medications. Drug-induced complications and mortality rates were also similar. The
GFR change rates of the patients in both groups were similar even though the initial GFRs were significantly higher in rivaroxaban
group. The mean age and ejection fractions of the patients using rivaroxaban 15 mg were found to be lower than those of patients
using rivaroxaban 20 mg whereas the mean systolic blood pressure and HAS-BLED score were found to be higher. Ischemic stroke and
mortality rates were higher in patients using 15 mg rivaroxaban than patients using 20 mg rivaroxaban. The rates of nonmajor bleeding
in patients using rivaroxaban 15 mg were lower compared to those using 20 mg, and this difference was statistically significant.
Conclusion: Stroke rates were found to be higher and to have similar bleeding rates compared to major clinical studies in our real-life
analysis. However, high ischemic cerebrovascular event and low nonmajor bleeding rates are remarkable in low dose use of rivaroxaban.
It is clear that there is a need to consider existing dose reduction criteria in terms of correct prescribing.
Key words: Rivaroxaban, apixaban, atrial fibrillation, ischemic stroke, appropriate dose

1. Introduction
Atrial fibrillation (AF) continues to be the most commonly
diagnosed rhythm disorder worldwide and the number of
diagnoses for the disorder has been increasing rapidly. Thus,
the prevalence of pathologies associated with AF increases
with age, the prevalence of AF increases in parallel to this
situation [1]. Stroke is one of the severe consequences of AF
[2]. Prevention of stroke and systemic thromboembolism
continues to be the cornerstone of AF treatment. A treatment
administered for this purpose, oral anticoagulation may
prevent most stroke cases stemming from AF [3,4]. Vitamin
K antagonists (VKA) and new generation oral anticoagulant
(NOAC) agents are used in this regard. NOACs have been
compared to warfarin in terms of efficiency and safety
and they have been approved in the treatment of AF in
the studies conducted. These studies have shown that
NOAC group medications are at least as effective as VKA
and safer at some points [5-8]. Following these studies,

real-life data began to be published and the efficacy and
safety results were compared according to major studies,
regional prescribing habits, and physicians’ approaches
were evaluated. Less selected cohorts in real-life studies can
help us understand the impact of NOACs in some specific
scenarios and situations compared to clinical studies [9].
However, anticoagulant therapies are long-term treatments
that do not target existing symptoms; medication adherence
is significantly lower in observational studies compared to
clinical studies [10-12].
Our aim in this study is to evaluate the real-life data of
the patients using rivaroxaban and apixaban, by utilizing
activity and safety parameters. Furthermore, the study aims
to determine certain parameters which can be crucial in
clinical practice, such as the properties of patient profiles,
prescription habits, how the dose reduction criteria are
evaluated, and to identify the similarities and differences
between these parameters and those of major studies.

* Correspondence: onuraslandr@gmail.com
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2. Materials and methods
This study was conducted in a state hospital, where 150
patients on average daily and 3000 patients applied annually.
Patients who were diagnosed with AF and started treatment
were included in the study among the patients who applied
to the hospital between 01 January 2018 and 31 December
2019. The patients included in the study were selected
retrospectively after the medication reports were issued in
order not to affect the treatment algorithm of the physicians
in this process. The patients in whom rivaroxaban (15–20
mg) and apixaban (2.5–5 mg) treatment started were
contacted and detailed information was given about the
study. Patients were followed up prospectively for 1 year.
Consent forms were signed by the patients who were eligible
for the study after 1 year.
The patients (n: 400) who accepted to participate in the
study in which rivaroxaban (15–20 mg) and apixaban (2.5–5
mg) were used after the diagnosis of AF, and whose records
were fully accessible through the hospital automation
system were included in the study. Patients who refused to
participate in the study (n: 146), whose medications were
changed for any reason (n: 38), who changed their city of
residence or hospital during their follow-up period (n: 92),
whose data were not fully accessible through the hospital
automation system (n: 19), and who were excluded from the
study due to other reasons (n: 5) were excluded from the
study (Table 1).
Patient data were obtained from the hospital automation
system and patient files and the data were recorded in a
previously prepared form. All emergency and hospital
applications of the patients were questioned during the
1-year follow-up period. The approvals of the patients were
obtained and their suitability for the study was evaluated
with a second format at the end of the follow-up period.
Rivaroxaban (15–20 mg) and apixaban (2.5–5 mg) were
started in 720 of 2900 patients with AF in a 2-year period,

and the data of 400 patients who completed the study and
met the inclusion criteria were analyzed.
The mortality information of the patients was confirmed
from hospital records and the death reporting system. A
medication tracking system in pharmacies was used to
verify the accuracy of the medications patients used. The
evaluation of major bleeding was made in accordance with
Internal Society on Thrombosis and Hemostasis (ISTH)
major bleeding criteria [13]. Any bleeding that the clinician
was aware of was considered nonmajor bleeding.
Atrial fibrillation was diagnosed according to
European Society of Cardiology (ESC) guidelines for the
diagnosis and management of atrial fibrillation developed
in collaboration with the European Association of CardioThoracic Surgery (EACTS).
Transient ischemic attack (TIA) and ischemic
cerebrovascular event (CVE) were described according
to the American Heart Association/American Stroke
Association (AHA/ASA) 2019 Updated Guidelines; TIA is
defined as an acute focal cerebral or ocular loss of function
whose symptom lasts shorter than 24 h and which is thought
to have been due to embolic or thrombotic vascular disease
after sufficient examination.
Patients who have acute restricted-diffusion in magnetic
resonance imaging (MRI), in addition to the neurological
symptoms, are considered to have ischemic CVE.
Modification of diet in renal disease (MDRD)
Calculation in glomerular filtration rate (GFR) calculation:
GFR=175 × ([Serum creatinine]–1.154) × ([Age]–0.203) × (0.742
if female) × (1.212 if black) was used.
Approval of local authority for this study had been taken
with the official paper no. E-66442466-604.01.01.
2.1. Statistical analysis
The data were recorded in the SPSS 17.0 package software.
Among the continuous variables, those with normal
distribution were expressed as mean ± standard deviation,

Table 1. Inclusion and exclusion to study randomization.
Patients with AF (n: 700) who were started with rivaroxaban and apixaban between 01.01.2018 and 31.12.2019
Patients who used rivaroxaban (15 mg and 20 mg) (n: 358)

Patients who used apixaban (2.5 mg and 5 mg) (n: 342)

Patients who refused to participate in the study (n: 86)

Patients who refused to participate in the study (n: 60)

Patients who underwent a change of medication for any reason Patients who underwent a change of medication for any
(n: 21)
reason (n: 17)
Patients who changed their city of residence or hospital during Patients who changed their city of residence or hospital
their follow-up period (n: 38)
during their follow-up period (n: 54)
Patients whose data were not fully accessible through the Patients whose data were not fully accessible through
hospital automation system (n: 8)
the hospital automation system (n: 11)
Patients who were excluded from the study due to other reasons Patients who were excluded from the study due to other
(n: 4)
reasons (n: 1)
Rivaroxaban (15 mg and 20 mg) group (n: 201)

Apixaban (2.5 mg and 5 mg) group (n: 199)
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and those without normal distribution were expressed as
the median (minimum–maximum); categorical variables
were expressed with numbers and percentages. The
Mann–Whitney U test was used in groups without normal
distribution, and Student’s t-test was used in groups with
normal distribution for the significance of the difference
between the means of the groups in continuous variables.
Pearson’s chi-squared test and, where appropriate, Fisher’s
exact test were used in order to test the significance of the
difference between categorical variables.
p-values less than 0.05 were considered statistically
significant.
3. Results
The number of women in our study was 194 (48.5%) of a
total of 400 patients using rivaroxaban and apixaban. The
mean age was 73.34 ± 10.45, and the age range was 41–98.
Of 201 patients using rivaroxaban, 44 (21.9%) used 15 mg
form, 157 (78.1%) used 20 mg form, and of 199 patients
using apixaban, 24 (12.1%) used 2.5 mg form, 175 (87.9%)
used 5 mg form. There was no significant difference in terms
of demographic characteristics, background information
of the patients, and the medications they used, when the
patients using rivaroxaban and apixaban were compared.
Medication-induced complications and mortality rates
were also similar. The CHA2DS2–VASc and HAS-BLED
scores were higher in the group in which apixaban was
started but this difference was not statistically significant.

Although the rates of ischemic stroke and TIA were lower
in the rivaroxaban group compared to the apixaban group,
this difference also was not statistically significant (p:
0.253). Major (p: 0.126) and nonmajor (p: 0.183) bleeding
rates were lower in the rivaroxaban group compared to the
apixaban group but there was no statistical significance.
The difference between all-cause mortality rates was also
statistically insignificant (p: 0.644). The GFR change rates
of the patients in both groups were similar, even though the
initial GFRs were significantly higher in the group in which
rivaroxaban was started (p: 0.015) (Table 2).
The mean age (p: 0.002) and ejection fractions (EF)
(p: 0.002) of the patients using 15 mg were found to be
lower (p: 0.008), whereas the mean systolic blood pressure
and HAS-BLED score were found to be higher (p: 0.005)
considering the comparison between the patients who
used rivaroxaban 15 mg and 20 mg. Ischemic stroke (p:
0.005) and mortality rates (p: 0.043) were higher in patients
using 15 mg rivaroxaban compared to patients using 20
mg rivaroxaban (Table 3). The rates of nonmajor bleeding
in patients using rivaroxaban 15 mg were lower compared
to those using 20 mg and this difference was statistically
significant (p: 0.047).
The mean age of the patients using 2.5 mg was higher
considering the comparison between the patients using
2.5 mg and 5 mg apixaban (p: 0.001). The background
characteristics, medications, complications, and mortality
rates of both groups were similar (Table 4).

Table 2. Demographic and clinical features.

Age

Apixaban (n: 199)

p-value*
0.292

72.69 ± 10.10

74.01 ± 9.85

Men

106 (52.7%)

100(50.3%)

Women

95(47.3%)

99(49.7%)

Weight

69.74 ± 8.41

68.31 ± 9.04

0.118

SBP

120.95 ± 14.79

122.19 ± 14.08

0.415

Paroxismal

8(4.0%)

11(5.5%)

Chronic

193(96.0%)

188(94.5%)

CHA2DS2–VASc

3.40 ± 1.45

3.57 ± 1.39

0.346

HAS-BLED

1.89 ± 0.74

1.97 ± 0.75

0.317

Gender

AF type
Application scores
EF

Background

950

Rivaroxaban (n: 201)

0.619

0.467

50.27 ± 9.53

49.40 ± 9.58

0.194

HT

176(87.6%)

181(91.0%)

0.273

DM

42(20.9%)

47(23.6%)

0.513

SVO

26(12.9%)

23(11.6%)

0.674

MI

31(15.4%)

44(22.1%)

0.087

PAH

5(2.5%)

2(1.0%)

0.229

Alcohol

2(1.0%)

0

0.252

Bleeding history

1(0.5%)

4(2.0%)

0.183
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Table 2. (Continued).
Beta blocker

172(85.6%)

176(88.4%)

0.393

CA channel blocker

60(29.9%)

66(33.2%)

0.475

ACEARB

174(86.6%)

174(87.4%)

0.796

Digoxin

85(42.3%)

98(49.2%)

0.163

Statin

70(34.8%)

79(39.7%)

0.314

NSAID

53(26.4%)

39(19.6%)

0.108

PPI

151(75.1%)

135(67.8%)

0.107

Amiodarone

3(1.5%)

3(1.5%)

0.653

Gastric medicines

38(18.9%)

32(16.1%)

0.457

ASA

4(2.0%)

6(3.0%)

0.369

Klopidogrel

2(1.0%)

2(1.0%)

0.685

TFT abnormality

17(8.5%)

13(6.5%)

0.465

Initial GFR

93.80 ± 38.93

83.73 ± 29.12

0.015

GFR change

1.03 ± 24.16

0.16 ± 25.04

0.889

Ischemic CVD

10(5.0%)

13(6.5%)

0.253

MI

3(1.5%)

5(2.5%)

0.356

PTE

0

1(0.5%)

0.498

DVT

3(1.5%)

0

0.126

Major bleeding

4(2.0%)

9(4.5%)

0.126

Minor bleeding

44(21.9%)

55(27.6%)

0.183

10(5.0%)

12(6.0%)

0.644

Ischemic CVD

8(4.5%)

11(6.2%)

0.487

MI

3(1.7%)

4(2.2%)

0.503

PTE

0

1(0.6%)

0.501

DVT

2(1.1%)

0

0.248

Major bleeding

4(2.3%)

8(4.5%)

0.192

Minor bleeding

36(20.3%)

48(27.0%)

0.142

9(5.1%)

12(6.7%)

0.508

Medications used

Complications

Mortality

Complications**

Mortality

*Mann–Whitney-U test, Pearson’s chi-squared test, and Fisher’s exact test
** Statistical analysis after excluding patients using inappropriate doses. Patients using appropriate doses of rivaroxaban
(n: 177) and apixaban (n: 178).

Low-dose rivaroxaban was started only in 28.6% (n: 8)
of the patients (n: 28) with a GFR of 15–50 mL/min when
evaluated according to the GFR, which is a dose-reduction
indication for rivaroxaban. Seventy-one point four percent
of patients with a GFR of 15–50 mL/min were started on
an inappropriately standard dose of rivaroxaban. Of the
patients (n: 15) who met two of the dose-reduction criteria
for apixaban (creatinine > 1.5, over 80 years old, below 60
kg), 33.3% (n: 6) were started with a low dose and 66.7% (n:
9) were started with a high dose. Among patients using 20
mg of rivaroxaban, 10.83% (n: 17) of the patients met dose
reduction criteria. When the same analysis was performed for

apixaban, up to 7.43% (n: 13) of the patients using 5 mg met
dose-reduction criteria.
Dose-reduction criteria were established during the
follow-up in 3.18% (n: 5) of the patients when the patients
using rivaroxaban 20 mg were evaluated, but their doses were
not reduced. On the other hand, it was observed for apixaban
that dose-reduction criteria were established in the follow-up
of up to 1.14% (n: 2) of the patients who used 5 mg, but no
dose reduction was made in these patients.
The mean age (p < 0.001), CHA2DS2–VASc (p: 0.002)
and HAS-BLED (p: 0.006) scores of the patients who died
were higher when the factors that may affect mortality
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Figure 1. Primary efficiency-safety end points and all-cause mortality rates for
rivaroxaban.

Figure 2. Primary efficiency-safety end points and all-cause mortality rates for
apixaban.

Figure 3. Systemic embolia and major + minor bleeding rates.
were examined. The mean ejection fraction was statistically
significantly lower in the deceased group (p < 0.001) (Table 5).
Complications and mortality numbers among patients
using rivaroxaban and apixaban are presented in Figures 1
and 2, and primary endpoints for both groups are presented
in detail in Figure 3.
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4. Discussion
The major finding of the study is remarkably high rates of
ischemic stroke and TIA in our real-life analysis. Secondly,
even though both the bleeding rates and stroke rates
tended to be higher in patients using apixaban compared
to the rivaroxaban group, it was not statistically significant.
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Table 3. Demographic and clinical features according to doses of rivaroxaban.
Rivaroxaban 15 (n: 44)

Rivaroxaban 20 (n: 157)

P-value*

77.32 ± 8.97

71.39 ± 11.19

0.002

Men

23 (52.3%)

72 (45.9%)

Women

21 (47.7%)

85(54.1%)

Weight

68.52 ± 9.03

70.08 ± 8.23

0.083

SBP

116.14 ± 16.03

122.29 ± 14.18

0.008

Paroxysmal

0

8 (5.1%)

Chronic

44 (100%)

149 (94.9%)

CHA2DS2–VASc

3.70 ± 1.34

3.31 ± 1.47

0.143

HAS-BLED

2.15 ± 0.57

1.81 ± 0.77

0.005

46.59 ± 10.10

51.31 ± 9.13

0.002

HT

42(95.5%)

134 (85.4%)

0.054

DM

5(11.4%)

37 (23.6%)

0.056

SVO

8(18.2%)

18(11.5%)

0.241

MI

4(9.1%)

27(172%)

0.139

PAH

0

5 (3.2%)

0.287

Alcohol

0

2 (1.3%)

0.609

Bleeding history

0

1 (0.6%)

0.781

Beta blocker

42(95.5%)

130(82.8%)

0.023

CA channel blocker

8 (18.2%)

52(33.1%)

0.056

ACEARB

41 (93.2%)

133(84.7%)

0.11

Digoxin

15 (34.1%)

70(44.6%)

0.213

Statin

44(100%)

157(100%)

0.636

NSAID

10 (22.7%)

43(27.4%)

0.535

PPI

33 (75.0%)

118(75.2%)

0.983

Amiodarone

0

3(1.9%)

0.475

Gastric medicines

12 (27.3%)

26(16.6%)

0.109

ASA

0

4(2.5%)

0.369

Klopidogrel

0

2(1.3%)

0.609

Ischemic CVD

5(11.4%)

5 (3.2%)

0.005

MI

1 (2.3%)

2(1.3%)

0.525

PTE

0

0

DVT

1 (2.3%)

2(1.3%)

0.525

Major bleeding

2 (4.5%)

2(1.3%)

0.209

Minor bleeding

5(11.4%)

39 (24.8%)

0.047

5(11.4%)

5(3.2%)

0.043

Age
Gender

AF type
Application
scores
EF

Background

Medications
used

Complications

Mortality

0.451

0.133

*Mann–Whitney U test, Pearson’s chi-squared test, and Fisher’s exact test

However, compared with rivaroxaban 20 mg stroke rates at
15 mg of rivaroxaban were strikingly high, and nonmajor
bleeding rates were again remarkably low.
Of the primary efficacy endpoints of major clinical
trials; ischemic stroke and TIA, which are the most
important treatment targets in patients with AF, were

found to be 5% (n: 10) in the rivaroxaban group and 6.5%
(n: 13) in the apixaban group. It was observed to be 3.2%
(n: 5) in the 20 mg group and 11.4% (n: 5) in the 15 mg
group considering the doses separately. It was determined
to be 6.3% (n: 11) in the apixaban 5 mg group and 8.3%
(n: 2) in the apixaban 2.5 mg group considering the doses
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Table 4. Demographic and clinical features and results according to doses of apixaban.
Apixaban 2.5 (n: 24)

Apixaban 5 (n: 175)

p-value*

80.21 ± 7.49

73.15 ± 9.85

0.001

Men

11(85.8%)

88 (50.3%)

Women

13(54.2%)

87 (49.7%)

Weight

67.46 ± 13.04

68.43 ± 8.40

0.395

SBP

120.83 ± 14.12

122.37 ± 14.11

0.578

Paroxysmal

0

11 (6.3%)

Chronic

24(100%)

164(93.7%)

CHA2DS2–VASc

3.79 ± 1.14

3.54 ± 1.42

0.176

HAS-BLED

2.08 ± 0.50

1.99 ± 0.78

0.443

Age
Gender

AF type
Application
scores
EF

Background

Medications
used

Complications

Mortality

0.682

0.234

48.33 ± 9.63

49.54 ± 9.59

0.368

HT

23(95.8%)

162(92.6%)

0.476

DM

4(16.7%)

43(24.6%)

0.283

SVO

3(12.5%)

20(11.4%)

0.547

MI

7(29.2%)

37(21.1%)

0.374

PAH

0

2(1.1%)

0.773

Alcohol

0

0

Bleeding history

0

4(2.3%)

0.615

Beta blocker

19(79.2%)

157(89.7%)

0.123

CA channel blocker

5(20.8%)

61(34.9%)

0.126

ACEARB

19(79.2%)

155(88.6%)

0.163

Digoxin

12(50.0%)

86(49.1%)

0.937

Statin

6(25.0%)

73(41.7%)

0.117

NSAID

2(8.3%)

37(21.1%)

0.108

PPI

15(62.5%)

120(68.6%)

0.55

Amiodarone

1(4.2%)

2(1.1%)

0.321

Gastric medicines

1(4.2%)

31(17.7%)

0.07

ASA

0

6(3.4%)

0.458

Klopidogrel

0

2(1.1%)

0.773

Ischemic CVD

2 (8.3%)

11 (6.3%)

0.615

MI

0

5(2.9%)

0.522

PTE

0

1(0.6%)

0.879

DVT

0

0

Major bleeding

2 (8.3%)

7(4.0%)

0.297

Minor bleeding

8(33.3%)

47(26.9%)

0.506

3(12.5%)

9(5.1%)

0.163

*Mann–Whitney U test, Pearson’s chi-squared test, and Fisher’s exact test

separately. These rates are remarkably higher compared to
the major clinical trials. At this point, these figures were
determined as 2.1% for the intention to treat the population
under the heading of stroke and systemic embolism in
the ROCKET-AF study (Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared With Vitamin K
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Antagonism for Prevention of Stroke and Embolism Trial
in AF), in which rivaroxaban was compared to warfarin
[14]. It was reported as 0.97% under the title of ischemic
or undetermined stroke in patients using apixaban in the
ARISTOTLE study (Apixaban versus Warfarin in Patients
with AF), in which apixaban was compared to warfarin

ASLAN and YILDIRIM. / Turk J Med Sci
Table 5. Demographic and clinical features of the deceased patients.
Deceased (n: 22)

ALIVE (n: 378)

p-value*

Rivaroxaban

10 (45.5%)

191 (50.5%)

Apixaban

12(54.5%)

187 (49.5%)

Age

80.73 ± 7.01

72.91 ± 10.47

Women

11 (50.0%)

195 (51.6%)

Men

11(50.0%)

183 (48.4%)

CHA2DS2–VASc

4.41 ± 1.22

3.43 ± 1.41

0.002

HAS-BLED

2.36 ± 0.73

1.90 ± 0.74

0.006

EF

41.82 ± 10.53

50.30 ± 9.30

<0.001

0.644
<0.001
0.885

*Mann–Whitney U test, Pearson’s chi-squared test, and Fisher’s exact test

[15]. Stroke and TIA were at the level of 0.9% in total
(16) in the XANTUS study (a real-world, prospective,
observational study of patients treated with rivaroxaban
for stroke prevention in atrial fibrillation), in which reallife data of rivaroxaban were analyzed. At this point, stroke
rates were significantly higher in all groups in our study
compared to major clinical studies. The reason for this
may be patients have less medication adherence in real
life and clinicians tend to decide on dose reduction based
on the frailty aspect of the patient rather than the criteria
for dose reduction. The fact that the patient risk profile in
major studies was higher than in real life may also have
played a role. Ischemic stroke data of patients using lowdose rivaroxaban are particularly striking.
The use of low dose apixaban was 12%, while the rate
of patients using low dose rivaroxaban was 21.8% in our
study. Low dose usage rates for ROCKET-AF and XANTUS
studies are 20.7% and 20.8%, respectively [14,16]. This
figure was given as 4.7% in the ARISTOTLE study (15).
The choice of low dose seems to be decided based on
the patient’s clinical evaluation. However, the lower dose
rate is higher in patients, such as older and with lower
EF, who may be considered more fragile by the clinician.
Only 28.6% of the patients with a GFR between 15 and
50 started low-dose rivaroxaban. Of the patients who had
two or more of the dose reduction criteria for apixaban
(creatinine >1.5, over 80 years old, under 60 kg), 33.3% of
the patients started on low doses. It was observed that up
to 10.83% of the patients had dose-reduction criteria when
the patients using rivaroxaban 20 mg were evaluated,
and up to 7.43% of the patients using 5 mg had dosereduction criteria when the same analysis was performed
for apixaban, but high dose medication was started instead
of low dose in these patients. In the XANTUS trial, 36%
of the patients were using rivaroxaban 20 mg even though
there was a dose reduction indication, whereas 15% of
the patients with a GFR >50 ml/min used rivaroxaban 15

mg even though they had no dose reduction criterion in
the XANTUS study (16). The rate of low-dose apixaban
use was reported to be 30.4% in another study evaluating
the use of NOAC [17]. Nine hundred and forty-three
patients were evaluated in another study in which the
use of inappropriate NOAC dose was investigated and it
was concluded that the low dose use rate was 13.6%, and
that 70.3% of patients who take low doses were taking
inappropriate doses. The rate of inappropriate high dose
use was found to be 3.7% in the same study. Low dose
use rates in real-life data show significant differences.
This difference is also apparent in major clinical trials of
apixaban and rivaroxaban. It is clear in light of these data
that current standards regarding dose reduction criteria
need to be further considered.
When evaluated in line with the primary safety
endpoint of major clinical trials, which are major and
nonmajor bleeding, the rates of bleeding in our study
have been %2 (n: 4) and 4.5% (n: 9) for rivaroxaban and
apixaban, respectively. The rates were 1.3% for rivaroxaban
(2) 20 mg and 4.5% (n: 2) for rivaroxaban 15 mg when we
evaluated the doses separately. The rate of major bleeding
in patients using apixaban according to the doses was 4%
(n: 7) for 5 mg, whereas it was 8.3% (n: 2) for 2.5 mg in
our study. Observing more major bleeding at lower doses
may have been due to the fact that low-dose patients
had more comorbidities and they were older patients.
A similar relationship is also present in the XANTUS
study results [16]. It was stated in the ROCKET-AF study
as 20.7% for rivaroxaban under the heading of major or
clinically related nonmajor bleeding [14]. This rate is 5.6%
when evaluated as any major bleeding. Major bleeding
was observed in 1.9% of patients when evaluated alone in
the XANTUS study. One of the most serious bleedings,
intracranial bleeding was detected in 1 patient (n: 4) in the
rivaroxaban group and in 1 patient (n: 9) in the apixaban
group in our study. It was reported as 0.8% in patients with
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ROCKET-AF and was found to be significantly lower than
warfarin [14]. Intracranial bleeding was detected as 0.4%
in the XANTUS study. Major bleeding was detected as
3.8% in the ARISTOTLE study (15). It was reported to be
0.5% when intracranial bleeding rates were considered.
Another parameter that may have an important place
in clinical practice and which may be significant in terms
of real-life data is the other bleeding that does not meet
the major bleeding criteria. There are studies showing that
these bleedings have predictive value for major bleeding
[18,19]. This condition, which we named nonmajor
bleeding in our study, was 21.9% for the rivaroxaban group
and 27.6% for apixaban. Nonmajor bleeding occurred in
13.6% (n: 6) of patients with rivaroxaban 15 mg and 24.2%
(n: 38) in the 20 mg group. It was observed in 16.7% of
patients with the heading of nonmajor clinical-related
bleeding in the ROCKET AF study. The bleeding rate
named nonmajor was given as 12.9% in patients using
rivaroxaban in the XANTUS study. Nonmajor bleeding
appears to be 12.1% in the ARISTOTLE study [20].
The patient population in our study had different
rates in certain parameters such as age, gender, AF type,
and the rate of patients with low EF, compared to major
studies. Similar figures were found in terms of diabetes,
hypertension, glomerular filtration rate, medications
used, and CHA2DS2–VAScand HAS-BLED scores [14,15].
Previous CVD and TIA history, which may be important
parameters, was 12.9% for the rivaroxaban group and
11.6% for the apixaban group in our patient population.
While the same rate was strikingly 54.9% in the ROCKETAF study, it was 19% in the ARISTOTLE study [21].
All-cause mortality rates were 5% in the rivaroxaban
group and 6% in the apixaban group in our study. It was
1.9%/year in the ROCKET-AF study and 3.52%/year in the
ARISTOTLE study. It was observed in our analysis that the
mean age was significantly higher and EF was significantly
lower in the patients who died. Comorbidities appear to be
the main determinant of all-cause mortality, as supported
by other studies.
There was no difference between the two groups in
terms of glomerular filtration rate. There was no difference
between the two groups again, and the rate of change was
similar when the change in glomerular filtration rates
was examined at the end of the study. Rivaroxaban and

apixaban were evaluated to be safer than warfarin in terms
of worsening of renal functions in a study comparing
warfarin in this regard [22]. The results in our analyses
also suggest that the use of rivaroxaban and apixaban does
not have a clear negative effect on renal function.
5. Conclusion
The first treatment goal of anticoagulation in AF patients
cerebrovascular with the disease, principally ischemic
stroke and TIA rates were found to be higher compared
with major clinical trials. Another important component
of these treatments, bleeding rates were similar to major
trials in our real-life analysis. Both efficacy and safety
parameters tended to be worse with apixaban but there
was no statistical significance. However, high ischemic
CVD and low nonmajor bleeding rates are remarkable in
low-dose use of rivaroxaban. More comprehensive studies
are needed on this subject. Considering the dose reduction
rates in the conducted studies, it is seen that the driving
factor for the dose reductions is clinicians’ evaluations,
rather than the standard criteria. We believe that the
existing criteria should be used more effectively in terms
of correct prescription to obtain maximum benefit from
the medication used.
6. Limitations
The most important limitation of this study is the singlecenter design. Follow-up time may be longer than 1 year
for larger-scale further studies.
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